Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
182 hedge funds and large institutions have $1.38B invested in Trillium Therapeutics Inc. in 2021 Q3 according to their latest regulatory filings, with 84 funds opening new positions, 46 increasing their positions, 36 reducing their positions, and 38 closing their positions.
121% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 38
118% more call options, than puts
Call options by funds: $85.4M | Put options by funds: $39.1M
69% more capital invested
Capital invested by funds: $820M → $1.38B (+$565M)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
33% more funds holding
Funds holding: 137 → 182 (+45)
28% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$38.2M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$36.7M |
| 3 |
OPU
Omni Partners US
Irvine,
California
|
+$27.7M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$26.9M |
| 5 |
VI
Versor Investments
New York
|
+$22.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$51.3M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$50M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$39.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$39.4M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$34.1M |
TRIL Hedge Fund Activity: Q3 2021 in Review
182 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q3 2021, worth a combined $1.38B — up 69% from $820M a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new TRIL positions and 38 closed out — a net gain of 46 holders — while 46 added to existing stakes and 36 trimmed.
The largest buyer was Magnetar Financial, opening a new position worth an estimated $38.2M. The largest seller was RA Capital Management, exiting entirely with an estimated $51.3M sold.
- 182 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q3 2021, up from 137 in Q2 2021.
- Funds reported $1.38B of Trillium Therapeutics Inc. stock for Q3 2021, up 69% quarter-over-quarter.
- 84 funds opened new Trillium Therapeutics Inc. positions in Q3 2021 and 38 closed out, a net change of +46 holders.
- The largest Trillium Therapeutics Inc. buyer in Q3 2021 was Magnetar Financial, an estimated $38.2M added.
- The largest Trillium Therapeutics Inc. seller in Q3 2021 was RA Capital Management, an estimated $51.3M sold.
Based on aggregated 13F filings for Q3 2021.